Previous close | 2.7100 |
Open | 2.7300 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 2.5100 - 2.7300 |
52-week range | 0.2000 - 3.1000 |
Volume | |
Avg. volume | 11,836 |
Market cap | 3.001M |
Beta (5Y monthly) | 3.31 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
ISTANBUL, Turkey, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp.'s (OTC: PRTT) President, Ali Yildiz, publishes his February 2024 corporate update letter to Company Shareholders as follows: "February 5, 2024 Dear Shareholders: Management announces that it has finalized its 2021 and 2022 financials, and the audit can be announced as completed. The Company is drafting a Form 10 registration statement that will be filed with the SEC to resume reporting to the SEC. The Company is als
ISTANBUL, Turkey, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp.’s (OTC: PRTT) President, Ali Yildiz, publishes a letter to Company Shareholders as follows: “Dear Shareholders of Protect Pharmaceutical Corp.: We have continued working with respect to finalizing our PCAOB audit. Our auditor has been granted access to the remaining areas that were needed and is finalizing the audit now. We are expecting the finalization of our audit for the calendar years 2021 and 2022 within the n
Istanbul, Turkey, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp. “OTC:(PRTT)” Ali Yildiz Addresses shareholders of the company. We wanted to update shareholders in regards to the progress on our PCAOB Audit. We had a small delay that originated from the auditor needing physical access to a secure facility that houses customs products. We believe the delay will be minimal and are still on track to finalize our audit within the next week to two weeks. We apologize for the unforesee